Market Place
Sourcing Support
Marker Therapeutics: 2025 Year-End Corporate and Financial
18 Mar 2026 //
GLOBENEWSWIRE
Marker Therapeutics at Oppenheimer 36th HCLS Conference
18 Feb 2026 //
GLOBENEWSWIRE
GMA Spotlights Baylor`s MAR-T Pancreatic Cancer Study
26 Jan 2026 //
GLOBENEWSWIRE
Baylor College Of Medicine Releases Positive Results
05 Jan 2026 //
GLOBENEWSWIRE
Marker Therapeutics Unveils Q3 2025 Financials & Business Result
14 Nov 2025 //
GLOBENEWSWIRE
Marker Therapeutics Appoints Kathryn Penkus Corzo To Board
05 Nov 2025 //
GLOBENEWSWIRE
Marker Therapeutics To Present MT-601 Data For Relapsed Lymphoma
03 Nov 2025 //
GLOBENEWSWIRE
Marker Therapeutics Treats First Patient In Off-The-Shelf Program
06 Oct 2025 //
GLOBENEWSWIRE
Marker to Join Fireside Chat at H.C. Wainwright Conference
28 Aug 2025 //
GLOBENEWSWIRE
Marker Therapeutics Updates Ph1 APOLLO Study in Relapsed Lymphoma
26 Aug 2025 //
GLOBENEWSWIRE
Marker Therapeutics Joins Chat at Canaccord Genuity Conference
30 Jul 2025 //
GLOBENEWSWIRE
Marker Therapeutics & Cellipont Bioservice Collaborate for MT-601
17 Jun 2025 //
GLOBENEWSWIRE
Marker: Lymphodepletion Boosts T Cells in Lymphoma Patients
20 May 2025 //
GLOBENEWSWIRE
Marker Therapeutics to Highlight MAR-T Cells in CAR-T Panel
19 May 2025 //
GLOBENEWSWIRE
Marker Therapeutics Reports 2024 Corporate and Financial Results
31 Mar 2025 //
GLOBENEWSWIRE
Marker Therapeutics to Present at H.C. Wainwright Conference
25 Feb 2025 //
GLOBENEWSWIRE
Marker Therapeutics Provides Clinical Update on MT-601 in Lymphoma
19 Dec 2024 //
GLOBENEWSWIRE
Marker Therapeutics Announces $16.1 Million Private Placement
19 Dec 2024 //
GLOBENEWSWIRE
Marker Awarded 9.5M Grant for MT-601 in Pancreatic Cancer
17 Dec 2024 //
GLOBENEWSWIRE
Marker Therapeutics to Present at Citizens JMP Hematology Summit
26 Nov 2024 //
GLOBENEWSWIRE
Marker Therapeutics Reports Q3 2024 Financial Results & Updates
14 Nov 2024 //
GLOBENEWSWIRE
Marker Therapeutics Reports Q2 2024 Financial Results And Business Updates
14 Aug 2024 //
GLOBENEWSWIRE
Marker Announces Clinical Program Updates and Pipeline Prioritization
08 Jan 2024 //
GLOBENEWSWIRE
Marker Therapeutics Announces Participation in Biotech Showcase
21 Dec 2023 //
GLOBENEWSWIRE
Marker Announces Complete Response in First Lymphoma Patient Treated with MT-601
11 Dec 2023 //
GLOBENEWSWIRE
Marker Announces Complete Response in First Lymphoma Patient Treated with MT-601
11 Sep 2023 //
GLOBENEWSWIRE
Marker Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Trial
12 Jun 2023 //
GLOBENEWSWIRE
